Osborne CK - Search Results

1

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Rimawi MF, et al. Among authors: osborne ck. Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7. Clin Cancer Res. 2011. PMID: 21138857 Free PMC article.

2

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Osborne CK, et al. J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746. J Natl Cancer Inst. 1995. PMID: 7563152

3

Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.

Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Reddy KB, et al. Among authors: osborne ck. Cell Growth Differ. 1994 Dec;5(12):1275-82. Cell Growth Differ. 1994. PMID: 7696176

4

Prognostic factors: rationale and methods of analysis and integration.

Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Clark GM, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1994;32(1):105-12. doi: 10.1007/BF00666211. Breast Cancer Res Treat. 1994. PMID: 7819579 Review.

5

Heat shock proteins and drug resistance.

Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Fuqua SA, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1994;32(1):67-71. doi: 10.1007/BF00666207. Breast Cancer Res Treat. 1994. PMID: 7819588 Review.

6

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. Osborne CK, et al. Cancer Chemother Pharmacol. 1994;34(2):89-95. doi: 10.1007/BF00685924. Cancer Chemother Pharmacol. 1994. PMID: 8194171

7

The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines.

Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. Oesterreich S, et al. Among authors: osborne ck. Cancer Res. 1993 Oct 1;53(19):4443-8. Cancer Res. 1993. PMID: 8402609

8

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.

Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Grøndahl-Hansen J, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1997 Apr;43(2):153-63. doi: 10.1023/a:1005744914124. Breast Cancer Res Treat. 1997. PMID: 9131271

9

Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.

Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D. Van den Berg CL, et al. Among authors: osborne ck. Eur J Cancer. 1997 Jun;33(7):1108-13. doi: 10.1016/s0959-8049(97)00071-3. Eur J Cancer. 1997. PMID: 9376191

10

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: osborne ck. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters